Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
United States
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Takeda in the U.S.
Worldwide Offices
Executive Leadership
Corporate Philosophy
Takeda Pricing Philosophy
Contact Us
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Research & Development
Our Pipeline
Therapeutic Areas
Patient Services & Assistance
U.S. Product List
Independent Medical Education Grants
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Corporate Responsibility
Purpose-led Sustainability
Sustainability underpins all we do at Takeda to help solve key societal challenges and create value for society.
Learn more
Patients
Patient Services and Assistance
Diversity, Equity & Inclusion in R&D
People
Diversity, Equity & Inclusion
Commitment to Community
Careers
Planet
Ethics and Compliance
Statements & Disclosures
HOME
Newsroom
US News Releases
Share:
Newsroom
US News Releases
Statements
NATPARA Updates
Global News Releases
US News Releases
Enter
All
Last 12 months
2022
2021
2020
2019
2018
2017
2016
October 2022
October 5, 2022
10/5/2022
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
September 2022
September 14, 2022
9/14/2022
Takeda Launches CDPATH™
June 2022
June 22, 2022
6/22/2022
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
April 2022
April 18, 2022
4/18/2022
Takedas TAKHZYRO Prefilled Syringe Now Available for People With HAE Ages 12 Years and Older in the United States
February 2022
February 9, 2022
2/9/2022
Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO®
January 2022
January 31, 2022
1/31/2022
FDA Approves Prophylactic Treatment with VONVENDI®
December 2021
December 21, 2021
12/21/2021
Takeda Receives Complete Response Letter from the US FDA for TAK-721
December 13, 2021
12/13/2021
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021
1
2
3
4
5
TOP
Close